Pentixapharm Holding AG · ISIN: DE000A40AEG0 · EQS - Company News

Pentixapharm Releases Interim Report for the Third Quarter of 2024

Pentixapharm Releases Interim Report for the Third Quarter of 2024 Loss of Pentixapharm Holding AG for the reporting period: €49k No revenue realized during the stub fiscal year through the end of Q3 Current liabilities of €487k, mainly from the purchase of Pentixapharm AG shares Berlin and Würzburg, Germany, November 12, 2024 – Pentixapharm Holding AG (ISIN: DE000A40AEG0), listed in the Prime Standard of the Frankfurt Stock Exchange, today published its consolidated interim report for the st...

XETR:PTP Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Pentixapharm Holding AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (1)
Short Selling (DE) (0)
Short Selling (UK) (0)
12 November 2024 05:45PM
Pentixapharm Releases Interim Report for the Third Quarter of 2024
DE000A40AEG0
Pentixapharm Releases Interim Report for the Third Quarter of 2024 Loss of Pentixapharm Holding AG for the reporting period: €49k No revenue realized during the stub fiscal year through the end of Q3 Current liabilities of €487k, mainly from the purchase of Pentixapharm AG shares Berlin and Würzburg, Germany, November 12, 2024 – Pentixapharm Hol...
Pentixapharm Holding AG
About the publication
04 November 2024 05:26PM
Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals
DE000A40AEG0
Berlin and Würzburg, Germany, November 4, 2024 – Pentixapharm, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, welcomes the recent announcement by the U.S. Centers for Medicare & Medicaid Services (CMS) to implement separate payments for specialized diagnostic radiopharmaceuticals used in the hospital outp...
Pentixapharm Holding AG
About the publication
29 October 2024 11:46AM
US National Cancer Institute Starts Advanced Clinical Trial with PentixaFor
DE000A40AEG0
Berlin and Würzburg, Germany, October 29, 2024 – The National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), two highly respected research organizations belonging to the US government's National Institutes of Health (NIH), have started a clinical trial involving 77 patients to see if Pentixa...
Pentixapharm Holding AG
About the publication
28 October 2024 12:26PM
Nuclear Medicine Specialist Ken Herrmann Joins Supervisory Board of Pentixapharm Holding AG
DE000A40AEG0
Berlin, Germany, October 28, 2024 – Prof. Dr. Ken Herrmann, a distinguished scientist and Head of the Department of Nuclear Medicine at Universitätsklinikum Essen, Germany, has as of today formally assumed his seat on the Supervisory Board of Pentixapharm Holding AG. While the appointment dates back to the shareholder meeting in June 2024 and has b...
Pentixapharm Holding AG
About the publication
25 October 2024 04:00PM
Upcoming Changes in the Management and Supervisory Boards of the Pentixapharm Group
DE000A40AEG0
Berlin, Germany, October 25, 2024 - Following the receipt of various approvals, consents, and registrations, Pentixapharm Holding AG will implement, at the end of October 2024, a series of changes to the group's management bodies. As announced, Dr. Hakim Bouterfa, founder and CEO of Pentixapharm AG, will step down from his positions on the Managem...
Pentixapharm Holding AG
About the publication
19 October 2024 12:28PM
Pentixapharm’s CXCR4 Core Compound Subject of 17 Abstract Presentations at the Hamburg European Association of Nuclear Medicine (EANM)
DE000A40AEG0
Hamburg, Germany, October 19, 2024 - The CXCR4 targeting compounds developed clinically by Pentixapharm in a number of diagnostic and therapeutic indications are subject of 17 abstract presentations at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) which takes place in Hamburg from 19 – 23 October 2024. The presenta...
Pentixapharm Holding AG
About the publication
18 October 2024 03:49PM
EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor
DE000A40AEG0
Würzburg and Berlin, Germany, October 18, 2024 - The European Medicine Agency (EMA) has granted PRIME Status to Pentixapharm’s lead candidate Ga68-PentixaFor, thereby granting an early and proactive support for the development of the radiodiagnostic and the possibility of an accelerated approval. The benefits of PRIME status include an early appoin...
Pentixapharm Holding AG
About the publication
03 October 2024 11:58AM
Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange
DE000A40AEG0
ADVERTISEMENT NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL Press Release Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange...
Pentixapharm Holding AG
About the publication
01 October 2024 06:48PM
Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed
DE000A40AEG0
NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL Disclosure of Insider Information according to Article 17 of Regulation (EU) No. 596/2014 Pentixapharm Holding AG: Place...
Pentixapharm Holding AG
About the publication
23 September 2024 12:15PM
Pentixapharm Holding AG Sets Price Range for Planned IPO
DE000A40AEG0
ADVERTISEMENT NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL Press Release Pentixapharm Holding AG Sets Price Range for Planned IPO Offering of up to 3.9 million new...
Pentixapharm Holding AG
About the publication
23 September 2024 12:15PM
Pentixapharm Holding AG Sets Price Range for Planned IPO
DE000A40AEG0
ADVERTISEMENT NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL Press Release Pentixapharm Holding AG Sets Price Range for Planned IPO Offering of up to 3.9 million new...
Pentixapharm Holding AG
About the publication
12 September 2024 03:00PM
Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange
DE000A40AEG0
ADVERTISEMENT NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL Press Release  Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime ...
Pentixapharm Holding AG
About the publication
12 September 2024 03:00PM
Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange
DE000A40AEG0
ADVERTISEMENT NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL Press Release  Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime ...
Pentixapharm Holding AG
About the publication
More Pentixapharm Holding AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 1 4th October 2024 Eckert Wagniskapital und Frühphasenfinanzierung GmbH DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN